Breathe BioMedical is proud to announce a $200,000 investment from the New Brunswick Innovation Foundation’s (NBIF) Start-up Investment Fund, and we are honoured to join their portfolio of high potential innovative companies.
“We are proud and grateful to reach this significant milestone with NBIF, who have been a longstanding partner with Breathe BioMedical,” said Dr. Stephen Graham, CEO at Breathe BioMedical. “This investment continues to build our breath analytic capacity in Moncton, which is creating a global centre of excellence for breath analytics right in New Brunswick. The due diligence completion is a testament to the operating state of the company and the ground-breaking work we are doing to change the landscape of disease screening in New Brunswick and beyond.”
To date, NBIF has invested a total of $360,000 into Breathe BioMedical, through their Start-up Investment Fund and their Innovation Voucher Fund non-repayable funding. These prior grants supported lung cancer studies and research at the University of New Brunswick, which helped to prove Breathe BioMedical technology’s ability to detect non-small cell lung cancer in the breath.
“Breathe BioMedical has great potential to make a significant impact not only here in New Brunswick for patients, researchers, partners and institutions but also globally. This investment helps put them at the forefront of breath analytics and revolutionary disease screening,” said Peter Goggin, Senior Investment Manager. “We are thrilled to have made another investment as a follow-on to our Innovation Voucher Fund investments. It supported their innovative technology development, and we can’t wait to see what is next for the company and the province.”
Breathe BioMedical has launched a new round of investment activity. To learn more about investment opportunities, email firstname.lastname@example.org
About Breathe BioMedical: Breathe BioMedical is a Canadian medical device company developing and manufacturing ground-breaking technology for breath analytics including our FDA-listed breath collection device SohnoXB™. Breath analytics involves the collection, processing and analysis of breath samples to identify biomarkers and patterns associated with specific diseases. Breathe BioMedical has completed proof-of-concept studies demonstrating our technology’s ability to detect non-small cell lung cancer in the breath with an accuracy of 86.1%; breast cancer with an accuracy of 81.4%; and COVID-19 pneumonia with an accuracy of 81.9%. Breathe BioMedical’s research and development laboratory is in Moncton, N.B. and its U.S. subsidiary is located in Boston, MA. One day, detecting disease will be as easy as breathing.
About NBIF: We help New Brunswick innovators solve globally relevant problems through research, solid advice and access to capital. We always represent the best interests of our portfolio. By leveraging their successes, we reinvest strategically to create new opportunities for New Brunswick.